Guaianolide Sesquiterpene Lactones, a Source To Discover Agents That Selectively Inhibit Acute Myelogenous Leukemia Stem and Progenitor Cells
Citations Over TimeTop 10% of 2012 papers
Abstract
Small molecules that can selectively target cancer stem cells (CSCs) remain rare currently and exhibit no common structural features. Here we report a series of guaianolide sesquiterpene lactones (GSLs) and their derivatives that can selectively eradicate acute myelogenous leukemia (AML) stem or progenitor cells. Natural GSL compounds arglabin, an anticancer clinical drug, and micheliolide (MCL), are able to reduce the proportion of AML stem cells (CD34⁺CD38⁻) in primary AML cells. Targeting of AML stem cells is further confirmed by a sharp reduction of colony-forming units of primary AML cells upon MCL treatment. Moreover, DMAMCL, the dimethylamino Michael adduct of MCL, slowly releases MCL in plasma and in vivo and demonstrates remarkable therapeutic efficacy in the nonobese diabetic/severe combined immunodeficiency AML models. These findings indicate that GSL is an ample source for chemical agents against AML stem or progenitor cells and that GSL is potentially highly useful to explore anti-CSC approaches.
Related Papers
- → CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia(2016)42 cited
- → HIV-1 infection depletes human CD34+CD38- hematopoietic progenitor cells via pDC-dependent mechanisms(2017)39 cited
- → CD34+/CD38−acute myelogenous leukemia cells aberrantly express Aurora kinase A(2013)35 cited
- → Differential MMP-9 activity in CD34+progenitor cell-derived foam cells from diabetic and normoglycemic patients(2013)
- → Progenitor cells and circulating endothelial cells are associated with disease activity and damage in systemic lupus erythematosus patients(2023)